Neupro Transdermal Patches (Rotigotine Others) 2mg/24hrs

Neupro transdermal patches deliver rotigotine 2mg/24hrs for consistent dopamine stimulation. Designed for ambient-temperature storage, these patches support steady relief for movement-related symptoms. Ideal for patients seeking discreet, once-daily application. Short-term use may help manage motor fluctuations.

Strength

2mg/24hrs

Pack Size

28s

Storage

Ambient

Manufacturer / TM Owner

UCB Pharma AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Rotigotine in Neupro patches is used to manage symptoms of Parkinson’s disease and restless legs syndrome. It helps smooth out motor fluctuations and reduce involuntary movements. Patients often use it when oral medications lose effectiveness. The 2mg/24hr strength provides a moderate dose for steady symptom control throughout the day.

Side Effects

Users typically report improved mobility and reduced tremors after applying Neupro patches. Some notice fewer sudden ‘off’ periods between doses. The patch format avoids stomach upset common with oral medications. Effects may take several days to become fully noticeable as the body adjusts to steady rotigotine levels.

Precautions & Warnings

Store Neupro patches at room temperature away from direct sunlight or heat sources. Apply to clean, dry skin on the abdomen, thigh, hip, or upper arm, rotating sites to avoid irritation. Avoid touching the sticky side before application. Keep used patches folded and out of reach of children and pets. Discard safely per local guidelines.

Avoid Interactions

Neupro may interact with medications that affect dopamine levels, such as antipsychotics or certain antidepressants. Alcohol and sedatives can increase drowsiness when combined with rotigotine. CYP enzyme inhibitors or inducers may alter rotigotine levels in the body. Always inform healthcare providers about all current medications before starting Neupro.

Frequently Asked Questions

Effects may appear gradually over several days as the body adjusts to steady rotigotine release.

No, cutting patches can disrupt the drug delivery system and is not recommended.

Replace it with a new patch at the next scheduled time; do not double up doses.

Consult a healthcare provider before using during pregnancy or breastfeeding.

Yes, the patch is water-resistant, but avoid prolonged exposure to hot water.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.